A cross-sectional study on the association of serum uric acid levels with depressive and anxiety symptoms in people with epilepsy

Rui Zhong1, Qingling Chen2, Mengmeng Li1, Nan Li1, Chaojia Chu1, Jing Li1, Xinyue Zhang1 and Weihong Lin1

Abstract

**Background:** High serum uric acid (SUA) levels may provide protection against depression and anxiety through its defensive role in oxidative damage. The aim of this study was to test the hypothesis of the independent associations of lower SUA levels with depressive and anxiety symptoms among patients with epilepsy (PWE).

**Methods:** A cross-sectional study was performed among 320 PWE aged ≥18 years old in Northeast China. The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 scale (GAD-7; Chinese version) were used as screening tools for depressive and anxiety symptoms for PWE. Serum uric acid levels were measured. The associations of SUA levels with depressive and anxiety symptoms were assessed by using binary logistic regression models, with adjustment for the related risk factors (P<0.05).

**Results:** Lower SUA tertiles were significantly associated with higher C-NDDI-E and GAD-7 scores compared with the higher two tertiles (p=0.001, and p= 0.002). Patients with depressive symptoms exhibited significantly lower SUA levels compared to those without depressive symptoms (p<0.001). SUA levels of patients with anxiety symptoms were significantly lower than those of patients without anxiety symptoms (p<0.001). The first and second SUA tertiles were associated with depressive symptoms, with the third tertile group as the reference group, after adjusting for confounders (first tertile: OR = 4.694, 95% CI = 1.643 ~ 13.413, P = 0.004; second tertile: OR = 3.440, 95% CI = 1.278 ~ 9.256, P = 0.014). However, The first and second SUA tertiles were not associated with the risk of anxiety symptoms compared with the third tertile in the adjusted logistic regression model (First tertile: OR = 1.556, 95% CI = 0.699 ~ 3.464, P = 0.279; second tertile: OR = 1.265, 95% CI = 0.607 ~ 2.635, P = 0.530).

**Conclusion:** We found that lower SUA levels were independently associated with depressive symptoms but not with anxiety symptoms among PWE. Further well-designed prospective cohort studies are required to determine the causality of the associations and to further clarify the mechanisms of SUA in depressive symptoms.

**Keywords:** Serum uric acid, Epilepsy, Depressive symptoms, Anxiety symptoms, Serum
Background

Epilepsy is one of the most common severe brain diseases and is characterized by a lasting predisposition to generating spontaneous epileptic seizures [1]. Epilepsy has been reported to affect more than 70 million individuals worldwide, constituting a major contributor to the global burden of neuropsychiatric disorders [1, 2]. Patients with epilepsy (PWE) have an increased prevalence of psychiatric comorbidities [3]. Depression and anxiety are the most common psychiatric comorbidities among PWE [3–5]. Approximately one third of PWE were diagnosed with depression or anxiety during their lifetime [6]. Even the mechanisms underlying the relationship between depression and epilepsy have not been properly investigated. Increasing evidences have indicated that depression and epilepsy such as temporal lobe epilepsy (TLE) represent an epiphenomenon sharing similar neural networks [7]. Mental health was related to poorer quality of life and worse prognosis in people with epilepsy [8–10]. These psychiatric comorbidities have a huge burden on patients, families and society [11]. Considering the high prevalence and significant burden of affective disorders in PWE, it is of importance to find more risk factors for psychiatric comorbidities in order to improve preventive strategies and find new therapeutic targets.

Serum uric acid (SUA), the end-product of purine metabolism, has been known as an important natural antioxidant in the human body [12]. Recent progress has indicated that oxidative stress may be involved in the pathogenesis of depression and anxiety [13, 14]. Lowered SUA levels have been reported as a potential contributor to the development of depression and anxiety [15, 16]. A large scale study based on 2875 subjects concluded that individuals with lower plasma uric acid levels have a higher risk of current but not remitted major depressive disorders and/or anxiety disorders, and this finding showed the benefit of uric acid on mental health [16]. In a cohort study of stroke patients, lower SUA levels on admission were found to be associated with poststroke depression at discharge [17]. In contrast, studies on the relationship between SUA levels and mental health have remained controversial. Li et al. found that adolescent depressive patients have higher SUA levels than controls [18]. There may be a complex relationship between SUA and epilepsy. A recent study reported a U-shaped association between SUA levels and epileptic seizures after cerebral infarction [19]. Some anti-epileptic drugs (AEDs) such as carbamazepine and phenobarbitone have been found to be associated with the levels of SUA in PWE [20].

We hypothesized that lower SUA levels may be related to psychiatric comorbidities in epilepsy. Thus, the aim of this study was to examine the association of SUA levels with depressive and anxiety symptoms among PWE. This study would add new knowledge on correlates of depressive and anxiety symptoms among PWE, apart from previous studies’ findings mainly on sociodemographic and epilepsy-related factors of these psychiatric comorbidities [17, 21].

Methods

Study sample

Study subjects were recruited from November 2017 to December 2019 among patients who were treated and followed up at the epilepsy clinic, Department of Neurology, The First Hospital of Jilin University. Epilepsy diagnosis was determined with the 2017 International League Against Epilepsy (ILAE) classification by a neurologist. The following inclusion criteria were used: (1) age ≥ 18 years old; (2) a definite epilepsy diagnosis; (3) without missing data on serum uric acid or psychological scale score; (4) written informed consent was provided. The exclusion criteria comprised: (1) a neurological disease other than epilepsy (e.g., dementia, Parkinson’s disease); (2) medical history of major psychiatric disorders; (3) a serious physical disease (e.g., significant hepatic, renal, or cardiopulmonary condition) or substance abuse history over the past 12 months. Overall, 320 participants were included in the final analysis.

Data collection

Two trained interviewers used a structured questionnaire to collect demographic and clinical data during a face-to-face interview. We recorded the following data: age, sex, body mass index (BMI), marriage status, education level, occupation, residence, per capita monthly family income, age at seizure onset, epilepsy duration, seizure type, seizure frequency in the last year, treatment type and > 50% nocturnal seizures. Body mass index was calculated as kg/m². The Neurological Disorders Depression Inventory for Epilepsy [22] (NDDI-E; Chinese version) and Generalized Anxiety Disorder-7 15 [23] (GAD-7; Chinese version) scales were used as screening tools for depressive and anxiety symptoms for PWE. All psychological evaluations were performed by two trained clinicians who were blinded to the data after receiving standardized training. Serum uric acid levels were measured.

Assessment of depressive symptoms

The NDDI-E scale [22] was used to assess the depressive symptoms of each patient. The NDDI-E scale is a rapid and user-friendly clinical instrument to screen for depressive symptoms in PWE [22]. The C-NDDI-E was validated in Chinese by Dong Zhou et al. and the Cronbach’s α coefficient for the C-NDDI-E was 0.825 [24]. It consists of six self-rated questions, with scores ranging from 1 to 4. The total score is obtained by summing the scores for the 6 questions; a higher C-NDDI-E score
indicates more serious depressive symptoms, and a score higher than 12 scale indicates depressive symptoms in PWE [24]. The C-NDDI-E is not a substitute for clinical interview or Diagnostic and Statistical Manual (4th ed.) diagnosis, but it is a reliable, validated, and widely used self-reported measure of depressive symptoms in mainland China [21].

Assessment of anxiety symptoms
The GAD-7 scale [23] is a valid and efficient tool for screening anxiety disorders and assessing their severity in clinical practice. In this study, the Chinese version of the GAD-7 was used to screen the comorbidity of anxiety symptoms in PWE, and the Cronbach’s α coefficient for the GAD-7 was 0.888 [25]. This questionnaire includes seven self-rating questions, with scores ranging from zero to three. A cutoff of > 6 indicates anxiety symptoms in patients [25].

Assessment of uric acid
Blood samples were collected from each patient and assessed to detect SUA levels in the Clinical Laboratory of the First Hospital of Jilin University. SUA was measured by using enzymatic colorimetry and a biochemical analyzer (7600–210, Hitachi, Japan). Total participants were divided into three groups according to tertiles of SUA levels, which ensured the most categories with adequate numbers of patients per subgroup. The cut-off values for stratification on the SUA level into tertiles were: (T1) \( n = 107 \), \( \leq 293 \) μmol/L; (T2) \( n = 107 \), 294–374 μmol/L; (T3) \( n = 106 \), \( \geq 375 \) μmol/L.

Statistical analyses
Continuous variables were presented as the means ± standard deviation (SD) or median and interquartile range, according to the normal or nonnormal distribution of the data tested by the Kolmogorov-Smirnov test. Categorical variables were presented as the frequencies and percentages. Student’s t test and analysis of variance (ANOVA) were used for the normally distributed continuous variables, while the Mann-Whitney U-test and Kruskal-Wallis tests were employed for the asymmetrically distributed variables. Chi-square tests were used for categorical variables. Additionally, post-hoc least significant difference (LSD) test and pairwise group comparisons were performed to investigate differences between any two groups using the Bonferroni correction, and \( P < 0.017 \) was deemed statistically significant in bonferroni correction. The associations of psychiatric comorbidities with SUA levels and other corresponding factors in PWE were assessed by binary logistic regression models and adjusted by related risk factors (\( P < 0.05 \)). We also tested for a linear trend across SUA tertiles in logistic regression models. Odds ratios (ORs) with 95% confidence intervals (CIs) in logistic regression models are presented. Analysis was performed with SPSS for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA). \( P < 0.05 \) was deemed statistically significant, and all statistical tests were two-sided.

Results
The sample comprised 320 subjects, 41.9% \( (n = 134) \) of which were female, with a mean (SD) age of 37.88 (15.94) years. The mean SUA level was 340.08 μmol/L. Depressive symptoms were prevalent in 20.3% \( (n = 65) \) of the patients and anxiety symptoms in 25.63% \( (n = 82) \). Demographic and clinical characteristics of the study sample are described in Table 1. All subjects were divided into three subgroups based on tertiles of SUA levels. General characteristics of subjects by the tertiles of SUA are presented in Table 1. A lower SUA tertile was significantly associated with higher C-NDDI-E and GAD-7 scores compared to higher tertiles (\( p = 0.001 \), and \( p = 0.002 \)). Patients in the tertile 1 group had higher C-NDDI-E scores than those in tertile 2 and tertile 3. Patients in the tertile 1 group had higher GAD-7 scores that those in tertile 3. Additionally, there were significant differences in age, gender, BMI, marital status, educational level, age at onset and seizure frequency over the last year between patients with the low, moderate, and high SUA levels. However, residence, disease duration, seizure type, monotherapy and >50% nocturnal seizures were not different between patients with the low, moderate, and high SUA levels.

The characteristics of patients with and without depressive/anxiety symptoms are summarized in Table 2. Patients with depressive symptoms exhibited significantly lower serum UA levels compared to those without depressive symptoms (\( p < 0.001 \)). Age, gender, educational level and per capita monthly family income showed significant differences between the group of patients with and without depressive symptoms. SUA levels of patients with anxiety symptoms were significantly lower than those of patients without anxiety symptoms (\( p < 0.001 \)). Gender, educational level, and seizure frequency in the last year were significantly different between patients with and without anxiety symptoms.

The association between SUA levels and depressive symptoms are presented in Table 3. Lower SUA levels were found to increase the risk of depressive symptoms among PWE, with the highest tertile group as the reference group. The first SUA tertile had a strong association with depressive symptoms in an unadjusted logistic regression model (OR 8.102, 95% CI 3.237–20.279, \( p < 0.001 \)). The second SUA tertile was also associated with depressive symptoms (OR 4.819, 95% CI 1.881–12.349, \( p = 0.001 \)). After adjusting for confounding factors in model 2 and model 3, the association
mentioned above still remained. The first tertile of SUA remained independently associated with the risk of depressive symptoms, with the third tertile group as the reference group after adjusting for confounders (model 2b: OR = 1.616, 95% CI = 1.415–5.123, P = 0.003). However, the association mentioned was no longer significant after adjusting for confounders (model 3c: OR = 1.556, 95% CI = 0.699–3.464, P = 0.279). The second SUA tertile was not associated with the risk of anxiety symptoms compared with the third tertile in the unadjusted and adjusted logistic regression models (model 1a: OR = 1.569, 95% CI = 1.450–2.704, P = 0.002; model 3c: OR = 1.415–5.123, P = 0.003). The association between SUA levels and anxiety symptoms described in Table 4. In the unadjusted logistic regression model, the first SUA tertile was significantly associated with the risk of anxiety symptoms compared with the third tertile (OR = 2.692, 95% CI = 1.415–5.123, P = 0.003). However, the association mentioned was no longer significant after adjusting for confounders (model 2b: OR = 1.616, 95% CI = 0.736–3.548, P = 0.231; model 3c: OR = 1.556, 95% CI = 0.699–3.464, P = 0.279). The second SUA tertile was not associated with the risk of anxiety symptoms compared with the third tertile in the unadjusted and adjusted logistic regression models (model 1a: OR = 1.569, 95% CI = 1.450–2.704, P = 0.002; model 3c: OR = 1.415–5.123, P = 0.003).
Table 2 Demographic and clinical characteristics of PWE according to depression and anxiety

| Variables                          | Depressive symptoms | Anxiety symptoms |
|-----------------------------------|---------------------|-----------------|
|                                   | (n=65)              | (n=255)         |                   |
|                                   | With symptoms       | Without symptoms|                   |
| SUA (umol/L), mean±SD             | 288.52 ± 60.05      | 353.22 ± 95.46  | < 0.001*          |
| Age (Years), mean±SD              | 42.77 ± 16.60       | 36.64 ± 15.56   | 0.009*            |
| Gender-female, n (%)              | 38 (58.5)           | 96 (37.6)       | 0.002*            |
| BMI (Kg/M2), mean±SD              | 23.21 ± 3.29        | 23.55 ± 3.95    | 0.516*            |
| Marital status-married, n (%)     | 46 (70.8)           | 159 (62.4)      | 0.207*            |
| Educational level, n (%)          | < 0.001*            | 0.005*          |
| University and above              | 10 (15.4)           | 85 (33.3)       |                   |
| Middle school                     | 40 (61.5)           | 153 (60.0)      |                   |
| Primary school and below          | 15 (23.1)           | 17 (6.7)        |                   |
| Residence-rural area, n (%)       | 24 (36.9)           | 91 (35.7)       | 0.853*            |
| Per capita monthly family income  |                      |                 |                   |
| (Yuan), (n %)                     | 12 (18.5)           | 19 (7.5)        |                   |
| <1000                             | 43 (66.2)           | 187 (73.3)      |                   |
| 1000–5000                         | 10 (15.4)           | 49 (19.2)       |                   |
| Age at onset (Years), median (IQR)| 37 (19, 48)         | 29 (16, 46)     | 0.085*            |
| Disease duration (Years), median (IQR)| 2 (1, 7)      | 2 (1, 6)        | 0.789*            |
| Seizure type-focal onset, n (%)   | 54 (83.1)           | 212 (83.1)      | 0.991*            |
| Seizure frequency over the last year, n (%) | 0.44*     | 0.03*          |
| Seizure-free                      | 11 (16.9)           | 52 (20.4)       |                   |
| 1–11                              | 31 (47.7)           | 133 (52.2)      |                   |
| >12                               | 23 (35.4)           | 70 (27.5)       |                   |
| Treatment-monotherapy, n (%)      | 57 (87.7)           | 229 (89.8)      | 0.624*            |
| >50% nocturnal seizures, n (%)    | 27 (41.5)           | 93 (36.5)       | 0.451*            |

SUA serum uric acid, BMI body mass index, PWE patients with epilepsy, IQR interquartile range, SD standard deviation, Student's t tests, Mann–Whitney U-tests and Chi-square tests were used in Table 2

Table 3 Binary logistic regression analyses for the association between SUA levels and depression in PWE

| Tertiles of SUA levels (umol/L) | Model 1a OR (95% CI) | P  | Model 2b OR (95% CI) | P  | Model 3c OR (95% CI) | P  |
|---------------------------------|----------------------|----|----------------------|----|----------------------|----|
| Tertile 1, n=107 (≤ 293)        | 8.102 (3.237, 20.279)| < 0.001 | 4.676 (1.650, 13.247)| 0.004 | 4.694 (1.643, 13.413)| 0.004 |
| Tertile 2, n=107 (294–374)      | 4.819 (1.881, 12.349)| 0.001 | 3.412 (1.272, 9.148)| 0.015 | 3.440 (1.278, 9.256)| 0.014 |
| Tertile 3, n=106 (≥ 375)        | 54.83 (18.5, 161)   | 0.026 | 68 (28.9)           | 0.956 | 198 (83.2)          | 0.956 |
| Per capita monthly family income (Yuan), n (%) | 0.03* | 0.03* |

OR odds ratio, CI confidence interval, SUA serum uric acid, PWE patients with epilepsy

Binary logistic regression analyses were used in Table 3

* adjusted for age, gender, BMI, marital status, educational level, and Per capita monthly family income

# adjusted for the terms in model2# plus age at onset and Seizure frequency over the last year
Depression and anxiety disorders, there may be a complex relationship between SUA levels and depressive symptoms in PWE. Our findings about the benefits of high SUA levels on depressive symptoms are consistent with several previous studies [15–17, 28]. A previous study demonstrated that SUA levels were significantly lower in individuals with depression or anxiety compared with healthy controls, and these data suggested that lowered SUA levels are a characteristic of depression [15]. A national population-based survey among 10,524 participants aged 45 years and above demonstrated that higher SUA levels were correlated with a decreased risk of depression in men but not in women [28]. In a Chinese cohort of stroke survivors, lower SUA levels on admission were associated with an increased risk of poststroke depression at discharge [17]. However, studies on the association of SUA levels with depression remain controversial [18, 29]. Gao et al. reported that higher SUA levels on admission were related with the occurrence of major poststroke depression within 3 months of stroke [29]. Li et al. found higher SUA levels in adolescent depressive patients, which could be used as a biomarker for the early diagnosis of depression in adolescents [18]. Two recent meta-analyses reported lower SUA levels in depression with high heterogeneity (I²=90%), indicating that the results have been inconsistent [30, 31].

The neuroprotective effects of SUA have been identified due to its antioxidant properties. Depression and anxiety disorders may share similar neurobiological mechanisms. However, we found that lower levels of SUA were independently associated with an increased risk of depressive symptoms but not anxiety symptoms after adjusting for related risk factors, which was not in line with a recent study [16]. Possible explanations may be the relatively small sample size in our study and the different diagnostic criteria of anxiety disorders among PWE. Thus, we aimed to investigate the association between SUA, depressive and anxiety symptoms in epilepsy.

The present study revealed that the prevalence of depressive symptoms was higher among PWE with lower SUA levels. We are unaware of any similar studies showing an association of SUA levels with depressive and anxiety symptoms in PWE. Our findings about the benefits of high SUA levels on depressive symptoms are consistent with several previous studies [15–17, 28]. A previous study demonstrated that SUA levels were significantly lower in individuals with depression or anxiety compared with healthy controls, and these data suggested that lowered SUA levels are a characteristic of depression [15]. A national population-based survey among 10,524 participants aged 45 years and above demonstrated that higher SUA levels were correlated with a decreased risk of depression in men but not in women [28]. In a Chinese cohort of stroke survivors, lower SUA levels on admission were associated with an increased risk of poststroke depression at discharge [17]. However, studies on the association of SUA levels with depression remain controversial [18, 29]. Gao et al. reported that higher SUA levels on admission were related with the occurrence of major poststroke depression within 3 months of stroke [29]. Li et al. found higher SUA levels in adolescent depressive patients, which could be used as a biomarker for the early diagnosis of depression in adolescents [18]. Two recent meta-analyses reported lower SUA levels in depression with high heterogeneity (I²=90%), indicating that the results have been inconsistent [30, 31].

The neuroprotective effects of SUA have been identified due to its antioxidant properties. Depression and anxiety disorders may share similar neurobiological mechanisms. However, we found that lower levels of SUA were independently associated with an increased risk of depressive symptoms but not anxiety symptoms after adjusting for related risk factors, which was not in line with a recent study [16]. Possible explanations may be the relatively small sample size in our study and the different diagnostic criteria of anxiety disorders among...
studies. Further well-designed prospective cohort studies with larger sample sizes are required to confirm the association between SUA levels and the risk of anxiety symptoms in patients with epilepsy.

Evidence indicated that elevations in SUA levels may be associated with anticipation of challenging stress situations [32]. A previous study found that SUA levels rose significantly in men who lose their jobs, while successful re-employment resulted in a return to normal SUA levels [33]. Additionally, stress situation is a common reported seizures precipitants in PWE, and Moon et al. found that the strongest predictor for perceived stress was depressive symptom in PWE [34]. These data supported the association between SUA levels, stress situation and depressive symptoms.

The present study illustrated that the risk of depressive symptoms was higher among participants with lower SUA levels. However, SUA levels were not associated with the risk of anxiety symptoms among PWE. We could not determine the potential mechanisms for the lower SUA levels in depressive symptoms among PWE. The current findings supporting a protective role of high SUA levels against depressive symptoms may be explained partly by the protective roles played by SUA in oxidative damage [35–37]. Oxidative damage and oxidative stress have been reported to play key roles in the development of depression and epilepsy [38–40]. Uric acid (UA) is known as an important natural antioxidant in the human body and plays a key role in the antioxidant capacity against oxidative and radical injury [12]. Lower SUA levels indicate lower antioxidant defences. Evidence has shown that lowered SUA levels lead to increased susceptibility to oxidative damage in the vulnerable brain due to its high oxygen consumption [41]. The brain is one of the most vulnerable organs due to its high metabolic rate. Reactive oxygen species (ROS) may lead to DNA and protein damage in the brain by reacting with these macromolecules. This damage may play an active role in the pathophysiology of affective disorders and make individuals susceptible to developing depression [42, 43]. Additionally, UA is a marker and the final product of purine metabolism. The purinergic system has been reported to be involved in the pathophysiology of affective disorders and is considered to influence mental health, cognition and sleep by the neurotransmitter adenosine triphosphate (ATP) and the neuromodulator adenosine, both of which are upstream metabolites of uric acid [44, 45].

Several limitations should be noted in our study. First, definitive conclusions about causality cannot be made given that our study was cross-sectional, and further prospective investigation is required to confirm our findings. Second, depressive and anxiety symptoms were diagnosed according to the scores of the C-NDDI-E and GAD-7 scales in this study. Clinical diagnosis is clearly the gold standard. While the C-NDDI-E is not a substitute for clinical interview or Diagnostic and Statistical Manual (4th ed.) diagnosis, it is a reliable, validated, and widely used self-reported measure of depression in mainland China [21, 24]. The Chinese version of the GAD-7 has also been validated in Chinese [25]. Third, the possibility of residual confounding factors cannot be excluded, although we adjusted for factors that could influence SUA levels or depressive symptoms among PWE. An important related risk factor is the anticonvulsants that may influence uric acid levels, anxiety and depressive symptoms in patients. Different types of anticonvulsants may have various impacts on uric acid levels, anxiety and depressive symptoms. Additionally, we divided all individuals into three groups according to tertiles of SUA levels, which was convenient for the statistical analysis. However, it may not have been a statistically or absolutely correct practice. The lack of a healthy control group was another limitation.

Conclusion
In conclusion, we found that lower SUA levels were independently associated with depressive symptoms but not with anxiety symptoms among PWE. These findings could offer in vivo evidence that SUA may play a role in the aetiology of depression. Our study also suggested that lower SUA levels might be used as an indicator of depressive symptoms among PWE. Further well-designed prospective cohort studies are required to determine the causality of the associations and to further clarify the mechanisms of SUA in depression.

Abbreviations
SUA: Serum uric acid; PWE: Patients with epilepsy; C-NDDI-E: Chinese Version of Neurological Disorders Depression Inventory for Epilepsy; GAD-7: Generalized Anxiety Disorder-7; ILAE: International League Against Epilepsy; ORs: Odds ratios; CIs: Confidence intervals; ROS: Reactive oxygen species; ATP: Neurotransmitter adenosine triphosphate

Acknowledgements
This work was supported by a grant from the Program of Jilin University First Hospital Clinical Cultivation Fund (LCPYJJ2017006). The authors would like to thank all of the participants for their valuable information, cooperation, and participation.

Authors’ contributions
RZ and WL led the study. RZ, QC and ML performed the data analysis and implemented the methodology. MI, NL, CC and JL collected the data. RZ prepared the original draft. WL reviewed and edited the final manuscript. RZ, QC, XZ and WL contributed to the revision. All authors read and approved the manuscript.

Funding
This work was supported by a grant from the Program of Jilin University First Hospital Clinical Cultivation Fund (LCPYJJ2017006). The abovementioned funding body had no further role in the study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the paper for publication.
Availability of data and materials
The deidentified database used in the current study is available from the corresponding authors on reasonable request.

Ethics approval and consent to participate
This cross-sectional study was carried out in the Department of Neurology, First Hospital of Jilin University. The Ethics Committee of the First Hospital of Jilin University (approval No. 2017–326) approved the study, and written informed consent was obtained from all participants or their legal representatives.

Consent for publication
Consent to publish the paper was obtained from all authors.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, The First Hospital of Jilin University, Chang Chun, China. 2Department of Hepatology, Tianjin Medical University, Tianjin Second People’s Hospital, Tianjin, China.

Received: 29 July 2020 Accepted: 20 December 2020
Published online: 07 January 2021

References
1. Thijss RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019; 393(10172):689–701.
2. Ouriques MS, Sacks C, Hacke W, Brainin M, de Assis FF, Marques PO, Lavados GP, Maninho MF, Hoppe WA, Vaca MD, et al. Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurol. 2019;18(7):674–83.
3. Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia. 2017;58(6):973–82.
4. Kwong KL, Lam D, Tsui S, Ngaan M, Tsang R, Lai SM. Anxiety and depression in adolescents with epilepsy. J Child Neurol. 2016;31(2):203–10.
5. Kwon OY, Park SP. Depression and anxiety in people with epilepsy. J Clin Neurol. 2014;10(1):173–88.
6. Rai D, Kerr MP, McManus S, Jordanova V, Lewis G, Brugha TS. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia. 2012;53(6):1095–103.
7. Veltrop KD, Busatto FG. Depression and temporal lobe epilepsy represent an epiophenomenon sharing similar neural networks: clinical and brain structural evidences. Arq Neuropsiquiatr. 2013;71(1):183–90.
8. Yeni K, Tulek Z, Simsek OF, Bebek N. Relationships between knowledge, attitudes, stigma, anxiety and depression, and quality of life in epilepsy: a structural equation modeling. Epilepsy Behav. 2018;85:212–17.
9. Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, Kanner AM, Caplan RP, Pilchigo S, Salpekar J, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13(Suppl 1):S1–S29.
10. Snoejen-Schouwenena NM, van Ooij JS, Tan IT, Aldenkamp AP, Schelhaas HJ, Hendriksen J. Mood, anxiety, and perceived quality of life in adults with epilepsy and intellectual disability. Acta Neurol Scand. 2019;139(6):19–25.
11. Plewin D, Smith N. Assessment and Management of Depression and Anxiety in children and adolescents with epilepsy. Behav Neurol. 2019;2019:2571368.
12. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uracil provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–62.
13. Steenkamp LR, Hough CM, Reus VJ, Jain FA, Epel ES, James SJ, Mofford AE, Melton SH, Wolkowitz OM, Lindqvist JD. Severity of anxiety- but not depression- is associated with oxidative stress in major depressive disorder. J Affect Disord. 2017;219:193–200.
14. Shafiee M, Ahmadnezhad M, Tayefi M, Arakhi S, Vatanparast H, Esmaeili H, Mohhebati M, Ferns GA, Mokhter N, Arefhossein SR, et al. Depression and anxiety symptoms are associated with prooxidant-antioxidant balance: a population-based study. J Affect Disord. 2017;219:193–200.
15. Wen S, Cheng M, Wang H, Yue J, Wang H, Li G, Zheng L, Zhong Z, Peng F. Serum uric acid levels and the clinical characteristics of depression. Clin Biochem. 2012;45(1–2):49–53.
16. Black CN, Bot M, Scheffer PG, Snieder H, Penninx B. Uric acid in major depressive disorders. J Affect Disord. 2018;225:684–90.
17. Li G, Miao J, Sun W, Song X, Lan Y, Zhao X, Qiu X, Zhang C, Zhu Z, Zhu S. Lower serum uric acid is associated with post-stroke depression at discharge. Front Psychiatry. 2020;11:52.
18. Tao R, Li H. High serum uric acid level in adolescent depressive patients. J Affect Disord. 2015;174:646–69.
19. Wang D, Hu B, Dai Y, Sun J, Liu Z, Feng Y, Cheng F, Zhang X. Serum uric acid is highly associated with epilepsy secondary to cerebral infarction. Neurotox Res. 2019;35(1):63–70.
20. Ring HA, Heller AJ, Marshall WJ, Johnson AL, Reynolds EH. Plasma uric acid in patients receiving anticonvulsant monotherapy. Epilepsy Res. 1991;8(3):241–4.
21. Wang HJ, Tan G, Deng Y, He J, He YJ, Zhou D, Liu L. Prevalence and risk factors of depression and anxiety among patients with convulsive epilepsy in rural West China. Acta Neurol Scand. 2018;138(6):541–7.
22. Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Valehe V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006;5(5):399–405.
23. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10): 1092–7.
24. Tong X, An D, Lan L, Zhou X, Zhang Q, Xiao F, Park SP, Kanemoto K, Kanner AM, Zhou D. Validation of the Chinese version of the neurological disorders depression inventory for epilepsy (C-NDDEI-E) in West China. Epilepsy Behav. 2015;47:6–10.
25. Tong X, An D, McGonigal A, Park SP, Zhou D. Validation of the generalized anxiety disorder-7 (GAD-7) among Chinese people with epilepsy. Epilepsy Res. 2016;120:31–6.
26. Togha M, Akhondzadeh S, Motamed M, Ahmadi B, Razeghi S. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Arch Med Res. 2007;38(3):313–6.
27. Li Q, Chen D, Zhu LN, Wang HJ, Xu D, Tan G, Zhang Y, Liu L. Depression in people with epilepsy in West China: status, risk factors and treatment gap. Seizure. 2019;66:89–96.
28. Li Y, Zhao L, Yu D, Ding G. Associations between serum uric acid and depression among middle-aged and elderly participants in China. Psychol Health Med. 2019;24(10):1277–86.
29. Gao J, Xu W, Han K, Zhu L, Gao L, Shang X. Changes of serum uric acid and total bilirubin in elderly patients with major poststroke depression stroke. Neuropsychiatr Dis Treat. 2018;14:83–93.
30. Liu T, Zhong S, Xiao C, Zhang C, Zhao P, Liu Y. A meta-analysis of oxidative stress markers in depression. PLoS One. 2015;10(10):e138904.
31. Jimenez-Fernandez S, Gurpegui M, Diaz-Atenza F, Perez-Costillas L, Gershenberg M, Correll CU. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. J Clin Psychiatry. 2015;76(12):1659–67.
32. Biersner RJ, McGHugh WB, Rehe RH. Biochemical and mood responses predictive of stressful diving performance. J Hum Stress. 1984;10(1):143–9.
33. Kadi SV, Cobb S, Brooks GW. Changes in serum uric acid and cholesterol levels in men undergoing job loss. JAMA. 1968;206(7):1500–7.
34. Moon HJ, Seo JG, Park SP. Perceived stress and its predictors in people with epilepsy. Epilepsy Behav. 2016;62:47–52.
35. Glantouzis GK, Tomoyannian EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145–51.
36. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis. 2007;17(6):409–14.
37. Dasgupta S, Dasgupta A, Mukhopadhayay T, Bhattacharya S, Swaila B, Banarjee U, Chakrabarty P. Serum uric acid: an early indicator of oxidative stress in beta thalassemia population. Mymensingh Med J. 2013;22(3):567–73.
38. SaUIM S. Oxidative stress and the central nervous system. J Pharmacol Exp Ther. 2017;360(1):201–5.
39. Black CN, Bot M, Scheffer PG, Cuypers P, Penninx BW. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology. 2015;51:164–75.
40. Geronds U, Lotti F, Grosso S. Oxidative stress in epilepsy. Expert Rev Neurother. 2018;18(6):427–34.
41. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013;18(5):595–606.
42. Bajpai A, Verma AK, Srivastava M, Srivastava R. Oxidative stress and major depression. J Clin Diagn Res. 2014;8(12):C4–7.
43. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(3):676–92.

44. Ortiz R, Ulrich H, Zarate CJ, Machado-Vieira R. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2015;57:117–31.

45. Ali-Sisto T, Tolmunen T, Toffol E, Vinnamaki H, Mantyselka P, Valkonen-Korhonen M, Honkala M, Ruusunen A, Velagapudi V, Lehto SM. Purine metabolism is dysregulated in patients with major depressive disorder. Psychoneuroendocrinology. 2016;70:25–32.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.